

ColoSTAT[®] Commercial Roll Out Expands With Further 4Cyte Pathology Sites and ColoSTAT[®] Access Program Participation

Highlights

- ✓ 4Cyte Pathology network expanded to seventy-eight activated commercial collection centres, representing an increase of over 100% since 18 March 2026.
- ✓ Commercial collection centres have now been activated in regional towns, in addition to the major urban centres, expanding the geographical access of ColoSTAT[®] to symptomatic patients.
- ✓ ColoSTAT[®] Access Program now has ten participating clinician sites across Victoria, New South Wales, and Queensland further supporting early-stage test utilisation and real-world evidence generation.
- ✓ Professor Finlay Macrae AO, Chair of Rhythm's Clinical Advisory Board, has joined the ColoSTAT[®] Access Program, adding clinical leadership and scientific rigour to the data collection effort.

Melbourne, Australia, 30th March 2026: Rhythm Biosciences Ltd ('RHY', the 'Company' or the 'Group') (ASX: RHY), a transformative, predictive cancer diagnostics technology company, provides an update on the continued expansion of its commercial ColoSTAT[®] testing network through its partnership with 4Cyte Pathology and growth in clinician participation under the ColoSTAT[®] Access Program.

Rhythm previously announced the first commercial sale of ColoSTAT[®] and highlighted the potential of scaling this process with 4Cyte Pathology (4Cyte) through the activation of commercial blood collection sites. The activated collection centres are co-located with clinics in which physicians are educated on the utility of ColoSTAT[®] and have ready access to the 4Cyte clinical test ordering platform.

ColoSTAT[®] Commercial Roll-Out: Collection Centre Activation

The first phase of Rhythm's commercial network rollout strategy with 4Cyte was previously announced on 18th March 2026 with thirty-eight commercial blood collection centres live in major urban centres.

Rhythm Biosciences Ltd
ACN 619 459 335
ASX: RHY

Australian Registered Address
Bio21 Molecular Science & Biotechnology Institute
30 Flemington Road
Parkville VIC 3010 Australia

Directors
Gavin Fox-Smith Non-Executive Chairman
Sue MacLeman Non-Executive Director
David Atkins CEO & Managing Director

www.rhythmbio.com

T +61 3 8256 2880
E info@rhythmbio.com

An additional forty blood collection sites have now been activated bringing the national total in ACT, NSW, Queensland and Victoria to seventy-eight.

The inclusion of sites in regional towns expands access to a broader patient population. Furthermore, to increase the accessibility, clinicians and patients can identify enabled ColoSTAT[®] Clinician referral and collection sites through a dedicated filter on the 4Cyte website via www.colostat.com/locations

The expansion of activated collection centres is a key driver of test accessibility and is expected to support increasing test volumes as clinician awareness and adoption grows.

The ColoSTAT[®] Access Program Update

The ColoSTAT[®] Access Program (the **Program**), announced on 11 February 2026, provides a structured pathway for early commercial adoption while generating real-world clinical evidence to support the ongoing commercialisation of ColoSTAT[®] as an aid for the triage and diagnosis of patients with symptoms of bowel cancer. The Program has now reached ten participating clinician sites across Victoria, New South Wales, and Queensland, with further enrolments in progress.

The Program has demonstrated early clinician engagement across both general practitioners and specialist surgeons. Notable among the participants is Professor Finlay Macrae AO, Chair of Rhythm's Clinical Advisory Board, whose enrolment reflects the Program's clinical credibility and the growing recognition of ColoSTAT[®] as a practical tool in the assessment of patients with symptoms of colorectal cancer. His participation is expected to support clinical confidence and broader adoption.

"We have ambitious targets for ColoSTAT[®], and I'm pleased to see the support from 4Cyte exceeding all expectations. The Program is an important market entry and real-world evidence collection platform and we're starting to get real momentum with the participation. Additionally, the Company is beginning to observe initial test ordering from symptomatic patients and in some sites re-ordering across activated 4Cyte sites." commented Dr David Atkins, Rhythm CEO & Managing Director.

The Company will provide further updates on the progress of the commercial ColoSTAT® rollout and test utilisation data becomes available through its regular reporting.

- ENDS -

This announcement was authorised by the Board of Directors of Rhythm Biosciences Limited.

For further information contact us via investors@rhythmbio.com.

About Rhythm Biosciences

Rhythm Biosciences Ltd (ASX: RHY) is an Australian innovative, medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. Rhythm is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer, and saving lives. Rhythm Biosciences is committed to working with likeminded global partners to achieve commercialisation and distribution of these simple solutions. The company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit rhythmbio.com and follow the company on LinkedIn and X.

About ColoSTAT®

Colorectal cancer (CRC), also referred to as bowel cancer, is the second leading cause of cancer deaths globally. If diagnosed early, colorectal cancer can be curable. The ColoSTAT® Test is Rhythm Bioscience's simple blood-based test for the detection of CRC. It measures five specific protein biomarkers that indicate the likelihood of CRC. It is intended for individuals with symptoms associated with Colorectal Cancer (CRC). The ColoSTAT® Test is based on research from Australia's CSIRO and is patent protected internationally. It has the potential to play a key role in reducing the mortality rate and healthcare costs associated with colorectal cancer.

About geneType™

geneType™ is a sophisticated genetic risk assessment testing platform that combines clinical, family history and genetic data to provide comprehensive risk assessments for various diseases. The platform leverages polygenic risk scores and clinical risk factors to generate personalized health insights, helping individuals and healthcare providers make more informed medical decisions. The technology allows for risk assessment across multiple conditions including breast cancer, cardiovascular disease, diabetes, colorectal cancer, prostate cancer, and melanoma. The tests are delivered through healthcare providers and genetic counsellors, ensuring appropriate clinical oversight and support for patients receiving their results. The platform's multi-disease assessment capabilities and clinical utility position it well to capture growing demand in the preventative healthcare and precision medicine markets. For more information, please visit www.genetype.com.

For personal use only